These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 18062275)

  • 1. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
    Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
    Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
    Xu F; Chen X; Shi A; Yang B; Wang J; Li Y; Guo X; Blackall PJ; Yang H
    Vet Microbiol; 2006 Dec; 118(3-4):230-9. PubMed ID: 16930871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.
    Liu J; Chen X; Lin L; Tan C; Chen Y; Guo Y; Jin M; Guo A; Bei W; Chen H
    Vaccine; 2007 Nov; 25(44):7696-705. PubMed ID: 17767980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1.
    Lin L; Bei W; Sha Y; Liu J; Guo Y; Liu W; Tu S; He Q; Chen H
    FEMS Microbiol Lett; 2007 Sep; 274(1):55-62. PubMed ID: 17608699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
    Liu J; Chen Y; Hu L; Bei W; Chen H
    Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):305-10. PubMed ID: 20518341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker.
    Bei W; He Q; Yan L; Fang L; Tan Y; Xiao S; Zhou R; Jin M; Guo A; Lv J; Huang H; Chen H
    FEMS Microbiol Lett; 2005 Feb; 243(1):21-7. PubMed ID: 15667996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and immunogenicity of a ∆apxIC/ompP2 mutant of Actinobacillus pleuropneumoniae and Haemophilus parasuis.
    Liu Q; Gong Y; Cao Y; Wen X; Huang X; Yan Q; Huang Y; Cao S
    Onderstepoort J Vet Res; 2013 Mar; 80(1):519. PubMed ID: 23718128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
    Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction and characterization of an attenuate strain apxIC-/P36+ of Actinobacillus pleuropneumoniae serovar 10].
    Zou H; Chen Y; Liu X; He Q; Chen P; Zhou R; Ma F; Wang Y
    Wei Sheng Wu Xue Bao; 2009 Sep; 49(9):1209-16. PubMed ID: 20030060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.
    Wang C; Wang Y; Shao M; Si W; Liu H; Chang Y; Peng W; Kong X; Liu S
    Vaccine; 2009 Sep; 27(42):5816-21. PubMed ID: 19654060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment of transmission of capsule-deficient, recombinant Actinobacillus pleuropneumoniae.
    Inzana TJ; Glindemann G; Fenwick B; Longstreth J; Ward D
    Vet Microbiol; 2004 Nov; 104(1-2):63-71. PubMed ID: 15530740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
    Chiang CH; Huang WF; Huang LP; Lin SF; Yang WJ
    Vaccine; 2009 Jul; 27(34):4565-70. PubMed ID: 19520199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of the znuA virulence factor attenuates Actinobacillus pleuropneumoniae and confers protection against homologous or heterologous strain challenge.
    Yuan F; Liao Y; You W; Liu Z; Tan Y; Zheng C; BinWang ; Zhou D; Tian Y; Bei W
    Vet Microbiol; 2014 Dec; 174(3-4):531-539. PubMed ID: 25465668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
    Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
    Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both ApxI and ApxII of Actinobacillus pleuropneumoniae serotype 1 are necessary for full virulence.
    Boekema BK; Kamp EM; Smits MA; Smith HE; Stockhofe-Zurwieden N
    Vet Microbiol; 2004 May; 100(1-2):17-23. PubMed ID: 15135509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
    Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
    Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.
    Xie F; Li G; Zhou L; Zhang Y; Cui N; Liu S; Wang C
    BMC Vet Res; 2017 Jan; 13(1):14. PubMed ID: 28061786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon.
    Prideaux CT; Lenghaus C; Krywult J; Hodgson AL
    Infect Immun; 1999 Apr; 67(4):1962-6. PubMed ID: 10085043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination.
    Prideaux CT; Pierce L; Krywult J; Hodgson AL
    Curr Microbiol; 1998 Nov; 37(5):324-32. PubMed ID: 9767712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
    Tonpitak W; Baltes N; Hennig-Pauka I; Gerlach GF
    Infect Immun; 2002 Dec; 70(12):7120-5. PubMed ID: 12438394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.